Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology

Haddox, Candace L.; Riedel, Richard F.

doi:10.1080/14737140.2020.1708198

Cited by 6 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical results on ICIs in STS have not shown strong improvements and trials have been slower in development, suggesting that more effort should be made to identify which patients are most likely to respond through predictive biomarker development [ 182 ]. Several trials of mono or combination checkpoint inhibitors have tried to identify the immune biomarkers expressed in STS that are relevant to clinical management and are summarized in Table 2 and Table 3 , respectively.…”

Section: Biomarkers In Clinical Trialsmentioning

confidence: 99%

Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level

Pillozzi

Bernini

Palchetti

et al. 2021

Cancers

View full text Add to dashboard Cite

Soft tissue sarcomas (STSs) are a heterogeneous group of rare tumors. Although constituting only 1% of all human malignancies, STSs represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. Over 100 histologic subtypes have been characterized to date (occurring predominantly in the trunk, extremity, and retroperitoneum), and many more are being discovered due to molecular profiling. STS mortality remains high, despite adjuvant chemotherapy. New prognostic stratification markers are needed to help identify patients at risk of recurrence and possibly apply more intensive or novel treatments. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the most relevant cellular, molecular and metabolic biomarkers for STS, and highlight advances in STS-related biomarker research.

show abstract

Section: Biomarkers In Clinical Trialsmentioning

confidence: 99%

Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level

Pillozzi

Bernini

Palchetti

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Ripretinib is being evaluated in an ongoing phase III study (INTRIGUE) as a second-line therapy in comparison with sunitinib after progressing on imatinib [89]. Recently, ripretinib is being investigated in clinical trials for systemic mastocytosis (SM) [90], and has been also proposed for the treatment of STS [91].…”

Section: Ripretinibmentioning

confidence: 99%

Diarylureas as Antitumor Agents

et al. 2021

View full text Add to dashboard Cite

The diarylurea is a scaffold of great importance in medicinal chemistry as it is present in numerous heterocyclic compounds with antithrombotic, antimalarial, antibacterial, and anti-inflammatory properties. Some diarylureas, serine-threonine kinase or tyrosine kinase inhibitors, were recently reported in literature. The first to come into the market as an anticancer agent was sorafenib, followed by some others. In this review, we survey progress over the past 10 years in the development of new diarylureas as anticancer agents.

show abstract

“…To date, doxorubicin remains the first-line chemotherapeutic drug for STSs ( Cojocaru et al, 2022 ; de Juan Ferre et al, 2021 ; von Mehren et al, 2020 ; Smrke et al, 2020 ; Smolle et al, 2020 ; Meyer and Seetharam, 2019 ; Yang et al, 2022 ; Gronchi et al, 2017 ). Selecting second- or higher-line drugs for advanced STS remains a challenge ( Frezza et al, 2017 ; Kim et al, 2019 ; Haddox and Riedel, 2020 ; Younger et al, 2021 ; Kojima et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Chemotherapeutic drugs for soft tissue sarcomas: a review

Tian

Yao

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Despite the low incidence of soft tissue sarcomas (STSs), hundreds of thousands of new STS cases are diagnosed annually worldwide, and approximately half of them eventually progress to advanced stages. Currently, chemotherapy is the first-line treatment for advanced STSs. There are difficulties in selecting appropriate drugs for multiline chemotherapy, or for combination treatment of different STS histological subtypes. In this study, we first comprehensively reviewed the efficacy of various chemotherapeutic drugs in the treatment of STSs, and then described the current status of sensitive drugs for different STS subtypes. anthracyclines are the most important systemic treatment for advanced STSs. Ifosfamide, trabectedin, gemcitabine, taxanes, dacarbazine, and eribulin exhibit certain activities in STSs. Vinca alkaloid agents (vindesine, vinblastine, vinorelbine, vincristine) have important therapeutic effects in specific STS subtypes, such as rhabdomyosarcoma and Ewing sarcoma family tumors, whereas their activity in other subtypes is weak. Other chemotherapeutic drugs (methotrexate, cisplatin, etoposide, pemetrexed) have weak efficacy in STSs and are rarely used. It is necessary to select specific second- or above-line chemotherapeutic drugs depending on the histological subtype. This review aims to provide a reference for the selection of chemotherapeutic drugs for multi-line therapy for patients with advanced STSs who have an increasingly long survival.

show abstract

Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology

Cited by 6 publications

References 35 publications

Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level

Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level

Diarylureas as Antitumor Agents

Chemotherapeutic drugs for soft tissue sarcomas: a review

Contact Info

Product

Resources

About